<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Increased <z:chebi fb="4" ids="30413">heme</z:chebi> catabolism has been reported in <z:chebi fb="105" ids="17234">glucose</z:chebi>-6-phosphate dehydrogenase (G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>)-<z:mpath ids='MPATH_458'>normal</z:mpath> neonates who were also homozygous for (TA)7/(TA)7 (UGT1A1*28) <z:chebi fb="0" ids="16704">uridine</z:chebi> diphosphoglucuronate-glucuronosyltransferase 1A1 (UGT) promoter polymorphism (<z:e sem="disease" ids="C0017551" disease_type="Disease or Syndrome" abbrv="">Gilbert syndrome</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>As <z:e sem="disease" ids="C0017758" disease_type="Disease or Syndrome" abbrv="">G-6-PD deficiency</z:e> is associated with <z:hpo ids='HP_0001878'>increased hemolysis</z:hpo>, we hypothesized that in G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient neonates who also have the (TA)7/(TA)7 UGT promoter genotype, steady-state <z:mp ids='MP_0010163'>hemolysis</z:mp> would be even further increased </plain></SENT>
<SENT sid="2" pm="."><plain>Male G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient neonates were sampled for plasma total <z:chebi fb="0" ids="16990">bilirubin</z:chebi> (PTB), blood carboxyhemoglobin corrected for inhaled <z:chebi fb="168" ids="17245">carbon monoxide</z:chebi> in ambient air (COHbc) (an index of <z:chebi fb="4" ids="30413">heme</z:chebi> catabolism), and UGT (TA)n promoter genotype determination and compared with previously published G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-<z:mpath ids='MPATH_458'>normal</z:mpath> neonates </plain></SENT>
<SENT sid="3" pm="."><plain>Although COHbc values were higher in the G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient than in the G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-<z:mpath ids='MPATH_458'>normal</z:mpath> cohorts (0.97 +/- 0.32% of total Hb (tHb) versus 0.76 +/- 0.19% of tHb, p &lt; 0.001), PTB values were similar (9.2 +/- 3.4 mg/dL versus 8.9 +/- 3.0 mg/dL, respectively, p = 0.3) </plain></SENT>
<SENT sid="4" pm="."><plain>Within the G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>-deficient group, although COHbc values were alike between the three UGT promoter genotypes, PTB was higher in the (TA)7/(TA)7 homozygotes (11.1 +/- 4.0 mg/dL) compared with (TA)6/(TA)7 heterozygotes (9.1 +/- 3.2 mg/dL, p = 0.03) and <z:mp ids='MP_0002169'>wild-type</z:mp> (TA)6/(TA)6 homozygotes (8.8 +/- 3.4 mg/dL, p = 0.02) </plain></SENT>
<SENT sid="5" pm="."><plain>In the steady state, similar rates of <z:mp ids='MP_0010163'>hemolysis</z:mp>, but increased PTB in the G-6-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PD</z:e>- deficient, (TA)7/(TA)7 homozygotes, imply that (TA)7/(TA)7, homozygosity is central to increased PTB </plain></SENT>
</text></document>